Viropharma introduces new reconstitution system for Cinryze
The company chooses the Mix2Vial needle-less reconstitution system for its therapy
International biopharmaceutical company ViroPharma Inc has begun packaging its therapry to prevent attacks of hereditary angioedema in West Pharmaceutical Services’ Mix2Vial needle-less reconstitution system.
Cinryze was approved by the US Food and Drug Administration in October 2008 for routine prophylaxis against hereditary angioedema (HAE) attacks in adolescents and adults.
“Since the launch of Cinryze, patients with HAE who are managed prophylactically with Cinryze - whether they have been trained by their healthcare provider to utilise our unique self administration option or have their physician administer their doses - have been empowered to take control of their lives,” said Daniel Soland, ViroPharma’s chief operating officer.
“Among our goals since the launch of Cinryze is that of continuously improving the entire Cinryze experience for our patients and physicians, and we have listened closely to their feedback. We believe that the use of the Mix2Vial in combination with Cinryze offers patients, care givers and physicians a needle-less system to encourage independence and simplify the reconstitution process.”
The Mix2Vial transfer device offers a needle-less reconstitution and transfer system and an asymmetrical vial skirt to help achieve new levels of simplicity in reconstituting Cinryze